share_log

Roth Capital Reinstates Buy on Apexigen, Announces $15 Price Target

Benzinga Real-time News ·  Jan 24, 2023 08:32

Roth Capital analyst Kumaraguru Raja reinstates Apexigen (NASDAQ:APGN) with a Buy and announces $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment